BrainsWay to Present at the 32nd Annual Oppenheimer Healthcare Conference

Rhea-AI Summary

Burlington, Mass., and Jerusalem, March 01, 2022 - BrainsWay Ltd. (NASDAQ: BWAY) announced that CEO Christopher von Jako, Ph.D., will present at the 32nd Annual Oppenheimer Healthcare Conference. The event will take place from March 15 to March 17, 2022, with BrainsWay's presentation scheduled for March 16 at 2:40 PM ET. The company specializes in noninvasive neurostimulation treatments for mental health disorders, including major depressive disorder and obsessive-compulsive disorder. Investors interested in meetings should contact their Oppenheimer representative.

BURLINGTON, Mass. and JERUSALEM, March 01, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that Christopher von Jako, Ph.D., President and Chief Executive Officer, will present and participate in one-on-one investor meetings at the 32^nd Annual Oppenheimer Healthcare Conference.

Event: 32^nd Annual Oppenheimer Healthcare Conference
Conference Date: Tuesday, March 15 – Thursday, February 17, 2022
Presentation: Wednesday, March 16, 2022, at 2:40pm ET

Management will also meet with investors during the event. Investors interested in meeting with the BrainsWay management team during the conference should contact their Oppenheimer & Co. representative.

About BrainsWay
BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal studies demonstrating clinically proven efficacy. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with offices in Burlington, MA and Jerusalem, Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit www.brainsway.com.

Contacts:
Scott Areglado
SVP and Chief Financial Officer
617-771-2287
SAreglado@brainsway.com

Investors:
Bob Yedid
LifeSci Advisors
646-597-6989
Bob@LifeSciAdvisors.com

FAQ

When is BrainsWay presenting at the Oppenheimer Healthcare Conference?

BrainsWay will present on March 16, 2022, at 2:40 PM ET during the Oppenheimer Healthcare Conference.

What is the ticker symbol for BrainsWay?

The ticker symbol for BrainsWay is BWAY.

What disorders does BrainsWay's Deep TMS technology treat?

BrainsWay's Deep TMS technology treats major depressive disorder, obsessive-compulsive disorder, and smoking addiction.

How can investors meet with BrainsWay management during the conference?

Investors can meet with BrainsWay management by contacting their Oppenheimer & Co. representative during the conference.

Where is BrainsWay headquartered?

BrainsWay is headquartered in Burlington, Massachusetts, and Jerusalem, Israel.